Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program
Journal of Leukocyte Biology · 04.11.2024 · 116 (5) · 1021-1032
DOI: 10.1093/jleuko/qiae152 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Leukocyte Biology, online erschienen am 06.07.2024. Verfasst von Gauthier Coussement und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, 808 Route de Lennik, 1070 Brussels, Belgium. Hauptthemen laut MEDLINE: Hypereosinophilic Syndrome, Antibodies, Monoclonal, Humanized, Compassionate Use Trials. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: FWO, F.R.S.-FNRS, National Fund for Scientific Research.
Abstract (Originalsprache)
Mepolizumab, an anti-interleukin-5 antibody, has been proven a safe and effective glucocorticoid (GC)-sparing drug for many patients with nonclonal hypereosinophilic syndrome (HES) and is now approved in many countries. It remains unclear, however, which patients are most likely to benefit from therapy and whether the currently approved dosing regimen is appropriate for all. This observational retrospective study included all patients with HES who were enrolled in the MHE104317 compassionate use program (CUP) in our center. Patient and disease characteristics, mepolizumab dosing, and both clinical and hematological responses to treatment were collected from medical files. Treatment responses and mepolizumab dosing requirements were analyzed according to disease characteristics. Eighteen patients with HES were enrolled in the CUP, of whom nine are still on treatment. The median duration of exposure to mepolizumab was 45 mo (maximum 18 yr). A lower number of affected organs, requirement for GC dosing ≤10 mg prednisone-equivalent, and single-organ HES were associated with a higher likelihood of complete response. Lymphocytic variant HES (L-HES) was less treatment-responsive, leading to withdrawal and/or requiring higher mepolizumab dosing to achieve some degree of disease control. In contrast, all patients with single-organ disease had a complete response that could often be maintained despite increasing between-dose intervals. Few potentially treatment-related adverse events were observed despite prolonged exposure. This study confirms the efficacy and safety of mepolizumab in HES, although patients with L-HES rarely experience a complete response. In contrast, patients with single-organ disease affecting the lungs are often super-responders, and decreasing mepolizumab dosing may be attempted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Hôpital Erasme, Université Libre de Bruxelles, 808 Route de Lennik, 1070 Brussels, Belgium.
- Institute for Medical Immunology, Université Libre de Bruxelles, 8 Rue Adrienne Bolland, 6041 Gosselies, Belgium.
Förderung
- FWO
- F.R.S.-FNRS
- National Fund for Scientific Research
- Excellence of Science
Zitieren
APA
Coussement, G., Catherine, J., & Roufosse, F. (2024). Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program. Journal of Leukocyte Biology, 116(5), 1021-1032. https://doi.org/10.1093/jleuko/qiae152
Vancouver
Coussement G, Catherine J, Roufosse F. Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program. Journal of Leukocyte Biology. 2024;116(5):1021-1032. doi:10.1093/jleuko/qiae152
BibTeX
@article{Coussement2024,
author = {Coussement, Gauthier and Catherine, Julien and Roufosse, Florence},
title = {Hypereosinophilic syndrome response to mepolizumab in the setting of a compassionate use program},
journal = {Journal of Leukocyte Biology},
year = {2024},
volume = {116},
number = {5},
pages = {1021--1032},
doi = {10.1093/jleuko/qiae152}
}
EUVIMED